Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

21. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

(95% CI, 1.51–2.28) Similar in men and women … Retrospective cohort of Kaiser Permanente Northwest Database 8231 +DM, 8845 no DM Up to 6 rates (person-years): DM: 30.9/1000 No DM: 12.4/1000 Rate ratio, 2.5 (95% CI, 2.3–2.7) … … CAD indicates coronary artery disease; DM, diabetes mellitus; ellipses (…), not reported; HF, heart failure; HR, hazard ratio; MESA, Multi-Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Examination Survey; and RR, relative risk. The risk of HF (...) via vascular smooth muscle cell proliferation and inflammation ( ). DM is also associated with more atherogenic dyslipidemia, in which low-density lipoprotein cholesterol particles are more atherogenic, and with endothelial dysfunction, which promotes leukocyte and platelet adhesion, thrombosis, inflammation, and coronary plaque ulceration. Figure 1. Pathophysiology of heart failure in diabetes mellitus. The hyperglycemia, insulin resistance, and hyperinsulinemia that often accompany diabetes

2019 American Heart Association

22. Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

, Beanlands RSB, Mielniczuk LM . N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T levels are related to the extent of hibernating myocardium in patients with ischemic heart failure. Can J Cardiol . 2017 ; 33:1478–1488. doi: 10.1016/j.cjca.2017.06.012 AlBadri A, Lai K, Wei J, Landes S, Mehta PK, Li Q, Johnson D, Reis SE, Kelsey SF, Bittner V, et al. . Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from (...) , Wagoner LE, et al. . A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A . 2006 ; 103:11288–11293. doi: 10.1073/pnas.0509937103 Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol . 2009 ; 54:432–444. doi: 10.1016/j.jacc.2009.05.009 Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich

2019 American Heart Association

23. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Full Text available with Trip Pro

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF (...) status have not been reported. The objective was to explore the effects of EQW on secondary end points in patients with and without baseline HF and test the effects of EQW on recurrent HHF events.The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease, analyzed EQW effects on all-cause death, each major adverse cardiac event component, first HHF, and repeat HHF, by baseline HF status

2019 EvidenceUpdates

24. Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure

Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure 1 Public Summary Document Application No. 1387.2 – Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure Applicant: Impulse Dynamics and Life Systems Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance (...) with its Terms of Reference, visit the MSAC website 1. Purpose of application An application for the resubmission of an implantable pulse generator (IPG) delivering Cardiac Contractility Modulation (CCM) therapy for patients with chronic heart failure was received from Impulse Dynamics Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness

2019 Medical Services Advisory Committee

25. Improving Communication in Heart Failure Patient Care (Abstract)

Improving Communication in Heart Failure Patient Care Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heart failure (HF) or other diseases. To prevent shocks at the end of life, clinicians should discuss deactivating the defibrillation function.The purpose of this study was to determine if a clinician-centered teaching intervention and automatic reminders increased ICD deactivation discussions and increased device deactivation.In this 6-center (...) , single-blinded, cluster-randomized, controlled trial, primary outcomes were proportion of patients: 1) having ICD deactivation discussions; and 2) having the shocking function deactivated. Secondary outcomes included goals of care conversations and advance directive completion.A total of 525 subjects were included with advanced HF who had an ICD: 301 intervention and 224 control. At baseline, 52% (n = 272) were not candidates for advanced therapies (i.e., cardiac transplant or mechanical circulatory

2019 EvidenceUpdates

26. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study (Abstract)

Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk.All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using

2019 EvidenceUpdates

27. Sacubitril/valsartan for chronic heart failure with reduced ejection fraction

Sacubitril/valsartan for chronic heart failure with reduced ejection fraction '); } else { document.write(' '); } ACE | Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Search > > Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction - Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has (...) not recommended listing sacubitril/valsartan on the Medication Assistance Fund (MAF) for treating chronic heart failure with reduced ejection fraction because of uncertain cost-effectiveness and budget impact at the price proposed by the manufacturer. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

28. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Full Text available with Trip Pro

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal (...) dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality

2019 Lancet

29. Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Last updated: March 19, 2019 Project Number: RB1316-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure? Key Message Two randomized controlled trials regarding the clinical effectiveness of ivabradine for patients with stable chronic heart failure were identified. Files Rapid Response Summary of Abstracts Published : March 19, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

30. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Last updated: May 15, 2019 Project Number: RC1119-000 Product Line: Research Type: Drug (...) Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure and with left ventricular ejection fraction > 35% and 40%? Key Message There were no studies identified with inclusion criteria of patients with stable chronic heart failure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

31. Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness (...) , and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 19, 2019 Project Number: RC1163-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and clinical utility of natriuretic peptide testing for the monitoring of heart failure therapy? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

32. Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness

Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments (...) : Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Last updated: August 27, 2019 Project Number: RB1380-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of point of care ultrasound for the assessment of patients with suspected or known chronic heart failure

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

. -,NO. -,2019 Hollenberg et al. -,2019:-–- Heart Failure Hospitalization Pathway 9TABLE 4 Key Comorbid Conditions to Consider Comorbidity Management Relevant Guidelines/Pathways Cardiovascular Coronary artery disease/acute coronary syndrome Assess and treat ischemia, and consider revascularization. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Atrial ?brillation/ ?utter (...) Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory EXPERT CONSENSUS DECISION PATHWAY 2019 ACC Expert Consensus Decision PathwayonRiskAssessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee Steven M. Hollenberg, MD, FACC, Chair Lynne Warner Stevenson, MD, FACC, Vice Chair Tariq Ahmad, MD, MPH, FACC Vaibhav J. Amin, MD

2019 American College of Cardiology

34. Cardiac rehabilitation for heart failure can improve quality of life and fitness. (Abstract)

Cardiac rehabilitation for heart failure can improve quality of life and fitness. The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac (...) -rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

35. Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure

Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Translation of the key statement of the final report N16-02 Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz (Version 1.2; Status: 4 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Extract of final report N16-02 Version 1.2 Telemonitoring using active cardiac implantable devices 4 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Telemonitoring using

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

36. Ivabradine (Lancora) for Heart Failure

Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure | CADTH.ca Find the information you need Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure Last updated: August 8, 2019 Project Number: HO0006-000 Product Line: Technology Review Result type: Report Heart failure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor

2019 CADTH - Technology Review

37. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (Abstract)

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo (...) -controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred

2019 NEJM

38. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. Full Text available with Trip Pro

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain.To determine whether NT (...) -proBNP changes in patients with HFrEF treated with sacubitril-valsartan correlate with changes in measures of cardiac volume and function.Prospective, 12-month, single-group, open-label study of patients with HFrEF enrolled in 78 outpatient sites in the United States. Sacubitril-valsartan was initiated and the dose adjusted. Enrollment commenced on October 25, 2016, and follow-up was completed on October 22, 2018.NT-proBNP concentrations among patients treated with sacubitril-valsartan.The primary

2019 JAMA

39. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling.To determine whether treatment of HFrEF with sacubitril-valsartan improves (...) central aortic stiffness and cardiac remodeling compared with enalapril.Randomized, double-blind clinical trial of 464 participants with heart failure and ejection fraction of 40% or less enrolled across 85 US sites between August 17, 2016, and June 28, 2018. Follow-up was completed on January 26, 2019.Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks.The primary outcome was change from

2019 JAMA Controlled trial quality: predicted high

40. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Full Text available with Trip Pro

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.We randomly assigned 4822 patients with New York Heart (...) Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening

2019 NEJM Controlled trial quality: predicted high